Molecularly defined AML classification using key defining rearrangements and mutations.
Calculated Interpretation
AML, NOS / requires integrated morphologic review
WHO 2022 / ICC 2022 classification is driven by defining molecular and cytogenetic lesions.
Guidelines & Evidence
Clinical Details
Section 1
When to Use
Primary Use
Molecularly defined AML classification using key defining rearrangements and mutations.
Section 2
Formula & Logic
Clinical Inputs
PML::RARA
Binary clinical feature
RUNX1::RUNX1T1
Binary clinical feature
CBFB::MYH11
Binary clinical feature
KMT2A rearrangement
Binary clinical feature
DEK::NUP214
Binary clinical feature
BCR::ABL1
Binary clinical feature
NPM1 mutation
Binary clinical feature
In-frame bZIP CEBPA mutation
Binary clinical feature
TP53 mutation
Binary clinical feature
Myelodysplasia-related gene mutation
Binary clinical feature
Myelodysplasia-related cytogenetics
Binary clinical feature
Interpretive Logic
Defining fusions and canonical mutations override morphology-only buckets.
Myelodysplasia-related AML is recognized by defining cytogenetic or gene features.
TP53-mutated AML is treated as a distinct high-risk biologic group.
Section 3
Pearls/Pitfalls
Result Bands
Fusion-defined AML
Examples include PML::RARA and core-binding factor AML.
Mutation-defined AML
Examples include NPM1-mutated and CEBPA-mutated AML.
MR-AML
Myelodysplasia-related AML category.
Section 4
Next Steps
Suggested Next Steps
01
Interpret the result in the full disease-specific clinical context.
02
Correlate with pathology, imaging, performance status, and multidisciplinary guidance.
Section 5
Evidence Appraisal
Evidence Base
Molecularly defined AML classification using key defining rearrangements and mutations.
OpiCalc Medical Oncology Module • Haematological Malignancies. 2026;Logic implemented from widely used contemporary oncology classification, prognostic, and response-assessment frameworks.
Section 6
Literature
Context
WHO 2022 / ICC 2022 AML is included in the oncology module as a structured decision-support tool for haematological malignancies workflows.
